Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013353436> ?p ?o ?g. }
- W3013353436 endingPage "1466" @default.
- W3013353436 startingPage "1461" @default.
- W3013353436 abstract "Abstract Background The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT 572 CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC). Methods A randomised, double blind, phase 2b trial, in HLA-A*201-positive patients with metastatic, TERT-expressing NSCLC, who did not progress after first-line platinum-based chemotherapy were randomised to receive either Vx-001 or placebo. The primary endpoint of the trial was OS. Results Two hundred and twenty-one patients were randomised and 190 (101 and 89 patients in the placebo and the Vx-001 arm, respectively) were analysed for efficacy. There was not treatment-related toxicity >grade 2. The study did not meet its primary endpoint (median OS 11.3 and 14.3 months for the placebo and the Vx-001, respectively; p = 0.86) whereas the median Time to Treatment Failure (TTF) was 3.5 and 3.6 months, respectively. Disease control for >6months was observed in 30 (33.7%) and 26 (25.7%) patients treated with Vx-001 and placebo, respectively. There was no documented objective CR or PR. Long lasting TERT-specific immune response was observed in 29.2% of vaccinated patients who experienced a significantly longer OS compared to non-responders (21.3 and 13.4 months, respectively; p = 0.004). Conclusion Vx-001 could induce specific CD8 + immune response but failed to meet its primary endpoint. Subsequent studies have to be focused on the identification and treatment of subgroups of patients able to mount an effective immunological response to Vx-001. Clinical trial registration NCT01935154" @default.
- W3013353436 created "2020-04-03" @default.
- W3013353436 creator A5001591653 @default.
- W3013353436 creator A5002761212 @default.
- W3013353436 creator A5006746765 @default.
- W3013353436 creator A5014087122 @default.
- W3013353436 creator A5021887337 @default.
- W3013353436 creator A5027946288 @default.
- W3013353436 creator A5028793195 @default.
- W3013353436 creator A5029860089 @default.
- W3013353436 creator A5045384053 @default.
- W3013353436 creator A5047544017 @default.
- W3013353436 creator A5049904099 @default.
- W3013353436 creator A5052962511 @default.
- W3013353436 creator A5053162824 @default.
- W3013353436 creator A5059355812 @default.
- W3013353436 creator A5059814520 @default.
- W3013353436 creator A5066083581 @default.
- W3013353436 creator A5077410158 @default.
- W3013353436 creator A5078704233 @default.
- W3013353436 creator A5080607522 @default.
- W3013353436 creator A5080809079 @default.
- W3013353436 creator A5080839939 @default.
- W3013353436 creator A5080841299 @default.
- W3013353436 creator A5083662358 @default.
- W3013353436 creator A5087963010 @default.
- W3013353436 creator A5088505116 @default.
- W3013353436 creator A5091733312 @default.
- W3013353436 date "2020-03-25" @default.
- W3013353436 modified "2023-10-18" @default.
- W3013353436 title "Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial" @default.
- W3013353436 cites W1060548536 @default.
- W3013353436 cites W1442200272 @default.
- W3013353436 cites W1980625858 @default.
- W3013353436 cites W1992699637 @default.
- W3013353436 cites W2035563280 @default.
- W3013353436 cites W2047984441 @default.
- W3013353436 cites W2056371902 @default.
- W3013353436 cites W2100912832 @default.
- W3013353436 cites W2102718441 @default.
- W3013353436 cites W2112621029 @default.
- W3013353436 cites W2114300639 @default.
- W3013353436 cites W2122476064 @default.
- W3013353436 cites W2136023414 @default.
- W3013353436 cites W2155846302 @default.
- W3013353436 cites W2160747045 @default.
- W3013353436 cites W2167129525 @default.
- W3013353436 cites W2291298003 @default.
- W3013353436 cites W2293531514 @default.
- W3013353436 cites W2404284208 @default.
- W3013353436 cites W2527833995 @default.
- W3013353436 cites W2612413465 @default.
- W3013353436 cites W2613155082 @default.
- W3013353436 cites W2724264513 @default.
- W3013353436 cites W2725858612 @default.
- W3013353436 cites W2728365508 @default.
- W3013353436 cites W2742120648 @default.
- W3013353436 cites W2784283849 @default.
- W3013353436 cites W2905858794 @default.
- W3013353436 cites W2912546216 @default.
- W3013353436 doi "https://doi.org/10.1038/s41416-020-0785-y" @default.
- W3013353436 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7217860" @default.
- W3013353436 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32210365" @default.
- W3013353436 hasPublicationYear "2020" @default.
- W3013353436 type Work @default.
- W3013353436 sameAs 3013353436 @default.
- W3013353436 citedByCount "18" @default.
- W3013353436 countsByYear W30133534362020 @default.
- W3013353436 countsByYear W30133534362021 @default.
- W3013353436 countsByYear W30133534362022 @default.
- W3013353436 countsByYear W30133534362023 @default.
- W3013353436 crossrefType "journal-article" @default.
- W3013353436 hasAuthorship W3013353436A5001591653 @default.
- W3013353436 hasAuthorship W3013353436A5002761212 @default.
- W3013353436 hasAuthorship W3013353436A5006746765 @default.
- W3013353436 hasAuthorship W3013353436A5014087122 @default.
- W3013353436 hasAuthorship W3013353436A5021887337 @default.
- W3013353436 hasAuthorship W3013353436A5027946288 @default.
- W3013353436 hasAuthorship W3013353436A5028793195 @default.
- W3013353436 hasAuthorship W3013353436A5029860089 @default.
- W3013353436 hasAuthorship W3013353436A5045384053 @default.
- W3013353436 hasAuthorship W3013353436A5047544017 @default.
- W3013353436 hasAuthorship W3013353436A5049904099 @default.
- W3013353436 hasAuthorship W3013353436A5052962511 @default.
- W3013353436 hasAuthorship W3013353436A5053162824 @default.
- W3013353436 hasAuthorship W3013353436A5059355812 @default.
- W3013353436 hasAuthorship W3013353436A5059814520 @default.
- W3013353436 hasAuthorship W3013353436A5066083581 @default.
- W3013353436 hasAuthorship W3013353436A5077410158 @default.
- W3013353436 hasAuthorship W3013353436A5078704233 @default.
- W3013353436 hasAuthorship W3013353436A5080607522 @default.
- W3013353436 hasAuthorship W3013353436A5080809079 @default.
- W3013353436 hasAuthorship W3013353436A5080839939 @default.
- W3013353436 hasAuthorship W3013353436A5080841299 @default.
- W3013353436 hasAuthorship W3013353436A5083662358 @default.
- W3013353436 hasAuthorship W3013353436A5087963010 @default.
- W3013353436 hasAuthorship W3013353436A5088505116 @default.
- W3013353436 hasAuthorship W3013353436A5091733312 @default.